Sol Gel Technologies Ltd logo

Sol Gel Technologies Ltd(SLGL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$55.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SLGL

11/13/2026: SLGL (1-star) is currently NOT-A-BUY. Pass it for now.

Sol-Gel Technologies is a specialty pharmaceutical company focused on the dermatology market, utilizing a unique silica-based microencapsulation platform. Its main strength lies in its portfolio of FDA-approved treatments, such as Twyneo and Epsolay, which provide a foundation for commercial revenue. The primary investment story centers on the successful market penetration of these products against entrenched competitors. Key risks include intense competition, limited commercial scale, and the company's history of financial losses. The stock may best suit growth-oriented biotech investors who can tolerate significant volatility. Investors should monitor prescription growth trends, potential licensing deals, and the company's efforts to achieve sustained profitability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the company has a niche technology and approved products, its growth trajectory remains dependent on successful commercial execution.
Momentum investorWeak fitThis stock often experiences low liquidity and volatility, making it less suitable for traditional momentum strategies.
Value investorWeak fitValuation is difficult to justify based on traditional metrics given the company's lack of consistent profitability.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for operations.
Low-risk investorWeak fitSmall-cap biotechnology stocks are inherently volatile and carry high execution and regulatory risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to significant swings based on clinical and commercial news.
Valuation riskMedium / highValuation is often tied to speculative success rather than current earnings.
Competition risk (dermatology market)HighPowerful competitors dominate the dermatology space, limiting market share potential.
Business qualityMediumThe company has a solid core technology but faces the inherent risks of a smaller firm.
Dividend incomeLow / noneThis is a growth-stage biotech with no dividend history.
Execution riskHighCommercializing products against entrenched rivals is difficult and resource-intensive.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 180.46M USD
Price to earnings Ratio -
1Y Target Price 155.5
Price to earnings Ratio -
1Y Target Price 155.5
Volume (30-day avg) 35.4K shares
Beta 1.24
52 Weeks Range 32.51 - 97.97
Updated Date 11/14/2026
52 Weeks Range 32.51 - 97.97
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -5.61

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 70.74%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SLGL receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SLGL has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+42.1%) and strong revenue growth (+68.0%) are partially offset by soft cash generation (FCF margin 1.4%), weak profitability (net margin -31.6%).

Financial Health Rating

★★★★★
SLGL's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 69.5%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is SLGL's strongest growth driver at +102.0% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+68.0%, strong) and earnings growth (+42.1%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 43.0% and approximately 10.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 59.73% supports management-shareholder alignment.

Top 5 Institutional Investors

Opaleye Management Inc 15.27%
Great Point Partners LLC 8.38%
Phoenix Financial Ltd 4.46%
Trails Edge Capital Partners, LP 4.26%
Affinity Asset Advisors, LLC 2.59%

Unit Economics (Per $1K Revenue)

★★★★★
SLGL generates approximately $1,000 of gross profit, $-389 of operating income, and $14 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SLGL has a Short Squeeze Candidate profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesRevenue generated from the sale of branded dermatology products like Twyneo and Epsolay in the US.The company earns money by convincing doctors to prescribe its specialized, patented acne and rosacea creams.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 9.34
Enterprise Value 135.76M
Price to Sales(TTM) 100.54
Enterprise Value 135.76M
Price to Sales(TTM) 100.54
Enterprise Value to Revenue 75.63
Enterprise Value to EBITDA 0.24
Shares Outstanding 3.27M
Shares Floating 352.54K
Shares Outstanding 3.27M
Shares Floating 352.54K
Percent Insiders 59.73
Percent Institutions 42.95

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.